Skip to main content

Instant redemption funds, UPI payments, KYC and more on the MobiKwik App!

Download
Home › Mutual Funds › Nippon Mutual Fund › Nippon India Pharma Fund - Direct Plan - Bonus Plan
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Bonus Plan

Add To Compare

previously known as Reliance Pharma Dir Bns until

NAV: ₹606.540 (-0.853%)
NAV on October 14, 2026
Category Equity:
Sector - Healthcare
Investment StyleBox
Total Assets ₹9,166 cr
Turnover Ratio 13.85%
Expense Ratio 0.99%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: Negative return: -4.99%
  • 1Y: Positive return: 6.53%
  • 3M: Negative return: -4.39%
  • 3Y: Positive return: 16.45%
  • 6M: Positive return: 8.88%
  • 5Y: Positive return: 12.56%
Min Investment ₹5,000
Buy Now Start SIP
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 21 years) Kinjal Desai (Since over 8 years) Amber Singhania (Since 7 months)
ISIN INF204K01I27
Fund Family Nippon
P/E Ratio 39.20
P/B Ratio 5.82
Launch Date January 01, 2013
Benchmark BSE Healthcare TR INR

Asset Allocation

  • Equity: 98.0%
  • Debt: 2.0%
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha -1.58
Beta 0.89
R-Squared 94.66
Info Ratio -0.90
Tracking Err 3.96
Sortino 1.239
Sharpe 0.755
Std Dev 15.068
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet

-


Other plans of Nippon India Pharma


Other Equity funds by Nippon

Data Partner Morningstar Logo – Data Partner
Visit AMC website to read all scheme related documents Nippon Fund